Miller Scientific Consulting, Inc., Arden, NC 28704, United States.
World J Gastroenterol. 2013 Aug 7;19(29):4718-25. doi: 10.3748/wjg.v19.i29.4718.
To determine the efficacy of probiotic supplementation on intestinal transit time (ITT) and to identify factors that influence these outcomes.
A systematic review of randomized controlled trials (RCTs) of probiotic supplementation that measured ITT in adults was conducted by searching MEDLINE and EMBASE using relevant key word combinations. Main search limits included RCTs of probiotic supplementation in healthy or constipated adults that measured ITT. Study quality was assessed using the Jadad scale. A random effects meta-analysis was performed with standardized mean difference (SMD) of ITT between probiotic and control groups as the primary outcome. Meta-regression and subgroup analyses were conducted to examine the impact of moderator variables on ITT SMD.
A total of 11 clinical trials with 13 treatment effects representing 464 subjects were included in this analysis. Probiotic supplementation was associated with decreased ITT in relation to controls, with an SMD of 0.40 (95%CI: 0.20-0.59, P < 0.001). Constipation (r (2) = 39%, P = 0.01), higher mean age (r (2) = 27%, P = 0.03), and higher percentage of female subjects (r (2) = 23%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression. Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation and in older vs younger subjects [both SMD: 0.59 (95%CI: 0.39-0.79) vs 0.17 (95%CI: -0.08-0.42), P = 0.01]. Medium to large treatment effects were identified with Bifidobacterium Lactis (B. lactis) HN019 (SMD: 0.72, 95%CI: 0.27-1.18, P < 0.01) and B. lactis DN-173 010 (SMD: 0.54, 95%CI: 0.15-0.94, P < 0.01) while other single strains and combination products yielded small treatment effects.
Overall, short-term probiotic supplementation decreases ITT with consistently greater treatment effects identified in constipated or older adults and with certain probiotic strains.
确定益生菌补充剂对肠转运时间(ITT)的疗效,并确定影响这些结果的因素。
通过在 MEDLINE 和 EMBASE 上使用相关的关键词组合,对益生菌补充剂治疗成年人 ITT 的随机对照试验(RCT)进行了系统评价。主要搜索限制包括在健康或便秘成年人中测量 ITT 的益生菌补充 RCT。使用 Jadad 量表评估研究质量。使用益生菌组和对照组之间 ITT 的标准化均数差(SMD)作为主要结局进行随机效应荟萃分析。进行荟萃回归和亚组分析,以检验调节变量对 ITT SMD 的影响。
本分析共纳入 11 项临床试验,共有 13 项治疗效果,涉及 464 名受试者。与对照组相比,益生菌补充剂与 ITT 降低相关,SMD 为 0.40(95%CI:0.20-0.59,P < 0.001)。便秘(r² = 39%,P = 0.01)、平均年龄较高(r² = 27%,P = 0.03)和女性受试者比例较高(r² = 23%,P < 0.05)是荟萃回归中与益生菌治疗 ITT 降低相关的预测因素。亚组分析表明,在有便秘和无便秘的受试者以及在较年轻和较年长的受试者中,益生菌治疗的 ITT 降低更为显著[均 SMD:0.59(95%CI:0.39-0.79)vs 0.17(95%CI:-0.08-0.42),P = 0.01]。双歧杆菌 Lactis(B. lactis)HN019(SMD:0.72,95%CI:0.27-1.18,P < 0.01)和 B. lactis DN-173 010(SMD:0.54,95%CI:0.15-0.94,P < 0.01)具有中等至较大的治疗效果,而其他单一菌株和组合产品则具有较小的治疗效果。
总的来说,短期益生菌补充剂可降低 ITT,在便秘或年长成年人以及某些益生菌菌株中,治疗效果更为显著。